| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
319,395,000 |
| Market
Cap: |
1.58(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.85 - $10.87 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, in vivo validation capabilities and a cross-functional team to discover medicines. Co.'s potential medicines include: REC-994 for the treatment of cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 for the treatment of familial adenomatous polyposis; REC-3599 for the treatment of GM2 gangliosidosis; REC-3964 for the treatment of C. difficile colitis; REC-64917 for neural or systemic inflammation; and multiple simultaneous programs in fibrosis developing with Bayer AG.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
845,786 |
1,900,560 |
2,119,134 |
3,656,718 |
| Total Sell Value |
$3,853,373 |
$9,354,510 |
$10,766,497 |
$23,763,487 |
| Total People Sold |
4 |
4 |
4 |
6 |
| Total Sell Transactions |
9 |
16 |
21 |
98 |
| End Date |
2025-10-23 |
2025-07-22 |
2025-01-21 |
2024-01-22 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gibson Christopher |
Director |
– • – |
2026-01-20 |
4 |
AS |
$4.47 |
$178,800 |
D/D |
(40,000) |
913,839 |
|
- |
|
| Gibson Christopher |
Director |
– • – |
2026-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
953,839 |
|
- |
|
| Borgeson Blake |
Director |
– • – |
2026-01-06 |
4 |
AS |
$4.36 |
$959,200 |
D/D |
(220,000) |
6,649,863 |
|
3% |
|
| Gibson Christopher |
Director |
– • – |
2026-01-05 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
913,839 |
|
- |
|
| Gibson Christopher |
Director |
– • – |
2026-01-05 |
4 |
AS |
$4.25 |
$170,000 |
D/D |
(40,000) |
933,839 |
|
7% |
|
| Gibson Christopher |
Director |
– • – |
2026-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
973,839 |
|
- |
|
| Dar Zavain |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,571 |
142,329 |
|
- |
|
| Li Dean Y |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,381 |
1,240,909 |
|
- |
|
| Hallett David |
CSOOfficer |
• – – |
2026-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
594,141 |
|
18% |
|
| Taylor Ben R |
Chief Financial Officer |
• – – |
2025-12-29 |
4 |
AS |
$4.18 |
$89,381 |
D/D |
(21,383) |
761,550 |
|
13% |
|
| Khan Najat |
Chief R&D Commercial Officer |
• • – |
2025-12-22 |
4 |
AS |
$4.41 |
$548,592 |
D/D |
(124,403) |
611,135 |
|
6% |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2025-12-19 |
4 |
AS |
$4.50 |
$180,000 |
D/D |
(40,000) |
913,839 |
|
10% |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2025-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
953,839 |
|
- |
|
| Taylor Ben R |
Chief Financial Officer |
• – – |
2025-12-15 |
4 |
D |
$4.33 |
$30,557 |
D/D |
(7,057) |
782,933 |
|
- |
|
| Borgeson Blake |
Director |
– • – |
2025-12-02 |
4 |
AS |
$4.37 |
$961,400 |
D/D |
(220,000) |
6,869,863 |
|
8% |
|
| Taylor Ben R |
Chief Financial Officer |
• – – |
2025-11-25 |
4 |
D |
$4.03 |
$9,152 |
D/D |
(2,271) |
789,990 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2025-11-19 |
4 |
AS |
$4.16 |
$166,400 |
D/D |
(40,000) |
913,839 |
|
16% |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2025-11-19 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
953,839 |
|
- |
|
| Taylor Ben R |
Chief Financial Officer |
• – – |
2025-11-17 |
4 |
D |
$4.14 |
$49,299 |
D/D |
(11,908) |
792,261 |
|
- |
|
| Khan Najat |
Chief R&D Commercial Officer |
• • – |
2025-11-17 |
4 |
D |
$4.14 |
$72,798 |
D/D |
(17,584) |
735,538 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2025-11-17 |
4 |
D |
$4.14 |
$167,215 |
D/D |
(40,390) |
913,839 |
|
- |
|
| Khan Najat |
Chief R&D Commercial Officer |
• • – |
2025-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
84,925 |
753,122 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2025-11-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
954,229 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2025-11-04 |
4 |
AS |
$5.21 |
$208,400 |
D/D |
(40,000) |
974,229 |
|
-7% |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2025-11-04 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
1,014,229 |
|
- |
|
831 Records found
|
|
Page 1 of 34 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.35 (7.59%) 
